Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness

Peggy J. Pazzaglia, Robert M. Post, Terence A. Ketter, Ann M. Callahan, Lauren B. Marangell, Mark A. Frye, Mark S. George, Tim A. Kimbrell, Gabriele S. Leverich, Gabriela Cora-Locatelli, David Luckenbaugh

Research output: Contribution to journalArticlepeer-review

88 Scopus citations


Of 30 patients with treatment-refractory affective illness, 10 showed a moderate to marked response to blind nimodipine monotherapy compared with placebo on the Clinical Global Impressions Scale. Fourteen inadequately responsive patients (3 unipolar [UP], 11 bipolar [BP]) were treated with the blind addition of carbamazepine. Carbamazepine augmentation of nimodipine converted four (29%) of the partial responders to more robust responders. Patients who showed an excellent response to the nimodipine-carbamazepine combination included individual patients with patterns of rapid cycling, ultradian cycling, UP recurrent brief depression, and one with BP type II depression. When verapamil was blindly substituted for nimodipine, two BP patients failed to maintain improvement but responded again to nimodiplne and remained well with a blind transition to another dihydropyridine L-type calcium channel blocker (CCB), isradipine. Mechanistic implications of the response to the dihydropyridine L-type CCB nimodipine alone and in combination with carbamazepine are discussed.

Original languageEnglish (US)
Pages (from-to)404-413
Number of pages10
JournalJournal of Clinical Psychopharmacology
Issue number5
StatePublished - Oct 1 1998

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)


Dive into the research topics of 'Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness'. Together they form a unique fingerprint.

Cite this